Outcomes
tumor
PROLIFERATION, TUMOR, SURGICAL COMPLICATION
The primary endpoint of the study was to evaluate the percentage of patients in each arm that achieved a reduction of at least 25% in Ki67 proliferation index, calculated as the difference of the measured Ki67 in tumor before and after treatment (ΔKi67). ΔKi67 ≥ 25% in pretreatment and posttreatment as a primary endpoint to test the hypothesis that olaparib would potentiate antitumor effects, was based on a previous WOO HNSCC study (Secondary efficacy endpoints included objective response rate (ORR) according to RECIST 1.1 criteria, and pCR rate. Surgical complication rate and number of participants with tolerability to treatment were the safety endpoints.